Despite its great efficiency some patient do not properly respond to eculizumab. This poor response it mostly due to genetic variations in the complement C5 gene, but also other complement genes can be affected theoretically.
Thrombotic microangiopathies | ||||
Hemolytic-Uremic Syndrome | ||||
Poor response to Eculizumab | ||||
C5 | ||||
Thrombotic Thrombocytopenic Purpura | ||||
1. |
Nishimura J et al. (2014) Genetic variants in C5 and poor response to eculizumab. |
2. |
OMIM.ORG article Omim 615749 |